INKT Stock Summary and Trading Ideas (Mink Therapeutics | NASDAQ:INKT)

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.

Mink Therapeutics trades on the NASDAQ stock market under the symbol INKT.

As of August 14, 2026, INKT stock price climbed to $11.27 with 6,603 million shares trading.

INKT has a beta of 1.67, meaning it tends to be more sensitive to market movements. INKT has a correlation of 0.13 to the broad based SPY ETF.

INKT has a market cap of $56.15 million. This is considered a Micro Cap stock.

In the last 3 years, INKT traded as high as $76.00 and as low as $.46.

The top ETF exchange traded funds that INKT belongs to (by Net Assets): VTI, VXF, IWC.

INKT has underperformed the market in the last year with a return of -26.4%, while SPY returned +21.5%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in INKT shares. However, INKT has outperformed the market in the last 3 month and 2 week periods, returning +7.2% and +7.3%, while SPY returned +4.0% and +3.9%, respectively. This indicates INKT has been having a stronger performance recently.

INKT support price is $10.40 and resistance is $11.60 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INKT shares will trade within this expected range on the day.